Skip to main content

Quotient Sciences’ Dr. Andrew Lewis Receives 2024 Distinguished Service Award from Controlled Release Society (CRS)

Awards & Recognition , Dr. Andrew Lewis

Quotient Sciences’ Dr. Andrew Lewis Receives 2024 Distinguished Service Award from Controlled Release Society (CRS)

Dr. Andrew Lewis

Dr. Andrew Lewis, Quotient Sciences’ Chief Scientific Officer, has been recognized by the Controlled Release Society (CRS) as a recipient of the 2024 Distinguished Service Award.

CRS established the award in 1994 to recognize CRS members who have exhibited exceptional commitment and service to the organization. Winners are selected by the CRS Board of Directors, composed of senior leaders and executives from academia and the pharmaceutical and biotech industry. An award ceremony will take place in July at the annual CRS global meeting in Bologna, Italy.

The Distinguished Service Award is not automatically given each year to a CRS member but only in cases where an exceptional member fits the criteria for having given sustained and outstanding service. Several factors determine a person’s eligibility for the award, including the person’s contributions to the development of high-impact, sustainable initiatives for the organization, the understanding and delivery of science and technology to various audiences, and the enhancement of the organization’s global membership and reach.

“Since its inception, the CRS has established itself as a world-leading organization for delivery science, providing forums for collaboration and knowledge sharing that have led to the development of many products that improve the quality of life of people globally,” said Dr. Lewis. “I am honored and humbled to be recognized for my contribution and thank the CRS for this award.”

Dr. Lewis has been a member of CRS for 20 years and has actively contributed to its development on a range of initiatives, including the Membership Committee, Scientific Advisory Board, and two tenures on the Board of Directors as Director-at-Large and most recently as Secretary.

Read the official announcement here.

Dr. Alan McNeill - Head of Isotope Labelling - Arcinova

Alan McNeill

Dr. Alan McNeill

Head of Isotope Labelling - Arcinova

Subject Expert
About

Dr. Alan McNeill has 30 years of experience in the pharmaceutical industry, both within large Pharma and CROs, in C-14 Radiosynthesis. From this, Alan has developed an in depth understanding of the requirements for a successful and cost-effective labelling strategy to deliver 14C labelled APIs to support pre-clinical and clinical studies. 

Alan holds a PhD in Organic Chemistry from the University of Manchester.
 

Expertise & focus areas

Dr. Richard Castledine - Head of Operations - Alnwick, UK - Arcinova

Richard Castledine

Dr. Richard Castledine

Head of Operations - Alnwick, UK - Arcinova

Executive Leader
About

Richard Castledine is responsible for the overall leadership responsibility for drug product and drug substance operations, project management, isotope labelling, quality control and bioanalysis services at our Alnwick, UK facility.

Richard has 15 years of experience in the pharmaceutical and contract development industries. Following the completion of his PhD, he worked briefly as a medicinal chemist before moving into process chemistry. Richard has led process development of over 25 programs at different stages of development ranging from pre-clinical and Phase I to process validation. 

He holds a PhD in synthetic organic chemistry from the University of Nottingham.

Expertise & focus areas

Dr. Mark Anstiss - Head of Drug Substance Operations - Arcinova

Dr. Mark Anstiss

Dr. Mark Anstiss

Head of Drug Substance Operations - Arcinova

Subject Expert
About

Dr. Mark Anstiss has over 15 years of experience in the pharmaceutical and fine chemical and industries spanning process research and development, process improvement, and drug substance manufacturing

Mark has a thorough understanding of the requirements for successful and safe scale up of chemical processes and has applied this knowledge to support the manufacture of early phase kilogram batches through to process improvement and optimization at tonne scale.  Throughout his career Mark has worked on the development and manufacturing of a significant number of psychoactive drug substances.  

Mark holds a Master of Chemistry degree from the University of Manchester and a PhD in Organic Chemistry from Leeds University.

Expertise & focus areas

Brad Rowe - Senior Director, Integrated Development

Brad Rowe

Brad Rowe

Senior Director, Integrated Development

Subject Expert
About

Brad Rowe joined the organization in 2005 and is based from our Philadelphia, PA sites in Garnet Valley and Boothwyn. He joined QS Pharma, later acquired by Quotient Sciences in 2017, initially working in the lab, and eventually was head of all analytical activities from the Philadelphia site. 

In his current role, Brad helps the business unit teams discuss and scope programs with customers, and supports program operations as a technical advisor throughout the lifecycle of a program.

Brad graduated from the University of Pittsburgh at Johnstown with a BS in Chemistry and then the University of Delaware with a PhD in Analytical Chemistry.

Quotient Sciences speaks with Outsourcing Pharma on what's ahead for CPhI

Translational Pharmaceutics®

Quotient Sciences speaks with Outsourcing Pharma on what's ahead for CPhI

This article from Outsourcing Pharma describes how our team at Quotient Sciences is looking forward to reconnecting with customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US at CPhI North America.

Topics discussed include how we plan to stay ahead of industry trends and developments, recent partnerships and collaborations, challenges we are facing and how these are being addressed, future expansion plans, and insight into what sets us apart from industry competitors.

Read the full article here on the Outsourcing Pharma website.

Outsourcing Pharma interview with Dr. Vanessa Zann

News & Announcements , Dr. Vanessa Zann , Artificial Intelligence

Outsourcing Pharma interview with Dr. Vanessa Zann

Dr. Vanessa Zann

In a recent interview with Outsourcing Pharma, Dr. Vanessa Zann, Senior Drug Development Consultant, speaks about her experience and Quotient Sciences' impact on drug development.

Dr. Zann highlights her past experience at Astra Zeneca and how she has carried that into her role at Quotient Sciences, noting the paramount importance of human data in guiding drug development decisions. She highlights case studies where Quotient Sciences has assisted in developing abuse-resistant opioid medications, notably with Ensysce Biosciences, and the role of artificial intelligence (Ai) in transforming drug development.

"AI has immense potential to streamline data analysis, predict formulation outcomes, and accelerate drug development processes. As AI continues to evolve, it promises to revolutionize pharmaceutical research and development, ushering in a new era of innovation and efficiency."

Read Delving into Quotient Science's pharma research and development on the Outsourcing Pharma website.

Colleague Stories: Omer Alp

Careers , Philadelphia , Omer Alp

Colleague Stories: Omer Alp

Omer Alp works at our Philadelphia, PA facility in planning and operational excellence (OpEx). In this interview, he shares what a day in the life in his role looks like.

Overall, leading teams and launching impactful products that improve patient lives I would have to say is the most rewarding part of my job. Collaborating and navigating complex projects is also incredibly fulfilling.

-Omer Alp

 

What does a Director, Integrated Planning and OpEx do at Quotient?

In my role at Quotient Sciences, I oversee the lifecycle management of commercial drug products manufacturing, ensuring client satisfaction and on time delivery. In a typical day, I spend my time developing and analyzing strategic KPI metrics for the operations, QC/AD lab, and project management departments. This helps to improve visibility for capacity management and enables better planning.

How has your career progressed since joining Quotient Sciences? 

Since joining Quotient Sciences, I've been promoted from a Senior Product Manager to a Director, and I have led Phase Il, Ill, and commercial drug projects from clinical trials to market readiness. Being in this role has allowed me to utilize my analytical, engineering, and business skills to lead cross-functional teams towards the completion of successful product launches and continuous improvement initiatives.

What experience did you have before Quotient Sciences?

My background includes roles in project management and process engineering. I have a mechanical engineering and business/program management background from Rowan University, and a leadership certificate from SineMuris Berlin. I have consistently applied this expertise to drive operational excellence. These qualifications have helped me better understand product management and strategic planning in the pharmaceutical industry. Immediately prior to joining the company, I was a Senior Project Manager at Thermo Fisher Scientific, where I led end-to-end technology transfer projects and helped reduce project lifecycle time by 20%.

What do you enjoy most about your role? What learning or qualifications have you gained since being here? 

Overall, leading teams and launching impactful products that improve patient lives I would have to say is the most rewarding part of my job. Collaborating and navigating complex projects is also incredibly fulfilling.

Since being at Quotient Sciences, I have been able to hone my skills in project management, planning, dashboard building, and Lean Six Sigma. In the pharmaceutical industry, given how dynamic it is, there is always something to learn as far as improving operational efficiency or with new technology for oral solid dose manufacturing, aseptic manufacturing, and other areas where Quotient Sciences operates.

What aspects do you find most challenging? 

In the pharmaceutical industry, it is crucial to integrate functions like formulation, quality control, and supply chain management while adhering to regulatory standards. Adaptability and innovation are essential to keep up with the fast-paced nature of the industry. Effective communication and collaboration are also especially important for those working in operations so we can ensure quality, safety, and efficacy when the product is delivered to our customers–and ultimately, to patients.

What advice would you give to someone applying for a role in your team?

At Philadelphia we have a diverse team. Collaboration is a big part of what we do, and we all share a common goal of delivering solutions that advance drug development. Success in our team comes from a combination of technical expertise, strategic thinking, and the ability to work collaboratively across disciplines. My advice to someone joining the company would be to be prepared to embrace challenges and have an open mind for continuous learning.

What do you like most about working at Quotient Sciences? 

The company stands for its commitment to scientific innovation and excellence in program delivery. The supportive culture, recognition of individual contributions, and the impact of our work on patient care have made working here an exceptional place to grow my career.

Executive interview at DCAT with Life Sciences Knowledge Hub featuring Thierry Van Nieuwenhove

Articles & Publications , Events , Thierry Van Nieuwenhove , Artificial Intelligence

Executive interview at DCAT with Life Sciences Knowledge Hub featuring Thierry Van Nieuwenhove

In a recent article with Life Sciences Knowledge Hub, Quotient Sciences executives speak to industry trends including artificial intelligence (Ai)

Thierry Van Nieuwenhove and Kieron Hall, Chief Marketing Officer, share insight about the role of artificial intelligence (Ai) and its impact to contract pharmaceutical manufacturing

“I think AI is a revolution for the industry,” says Thierry Van Nieuwenhove, CEO of Quotient Sciences, “This is really what’s going to change the industry substantially. And the whole industry is still looking at how this could actually accumulate, being implemented into the shop and into the value chain of developing a drug but also later on of adding a drug on the market.”

Read the full article, "Looking Back at DCAT Week 2024," on the Life Sciences Knowledge Hub website.

Rationalizing the Preclinical-Clinical Hurdle – How to Overcome the Toxicology Exposure Challenge

On-Demand Webinars , Preclinical , Formulation Development

Rationalizing the Preclinical-Clinical Hurdle – How to Overcome the Toxicology Exposure Challenge

26 March 2024
Overview

This webinar will explore navigating the preclinical to clinical transitions with a focus on addressing toxicology exposure challenges. 

 

Join our speakers Andrew Parker and Valeria Ciarnelli as we delve into regulatory framework and the needs of enabling technologies for poorly soluble molecules.

In this presentation, Dr. Valeria Ciarnelli, Senior Director of Product Development, and Dr. Andrew Parker, Senior Drug Development Consultant, will discuss considerations when navigating the pre-clinical to clinical transition, delving into the regulatory expectations and the needs of enabling technologies for poorly soluble molecules, among other topics.

Our speakers will review the solutions that our team have developed to help customers successfully navigate through development milestones, leveraging the Quotient Sciences Translational Pharmaceutics® platform. They will share rationale for assessing amorphous solid dispersions when compared with lipidics and size reduction, and show how these can be easily translated into fit-for-purpose, first-in-human (FIH) presentations suitable for oral administration and enabling dose escalation. 

Key learning objectives:

  • How to identify the best development strategy, technology(s) and candidate(s), demonstrate solubility improvement and stability.
  • Justify selection of prototypes as being suitable for testing in animals and potentially improving exposure to meet toxicology multiples required to justify entering a FIH study.
  • Where to invest from early stage, modularity of the preclinical screen and how it can be refined based on your needs.

Watch
Date
26 March 2024
Subscribe to